ArticleOncogene2007
Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia.Medical oncology (Northwood, London, England) · 2021Article
- Further dissection of QTLs for salt-induced stroke and identification of candidate genes in the stroke-prone spontaneously hypertensive rat.Scientific reports · 2018Article
- Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.Current pharmaceutical biotechnology · 2018Review
- The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.Oncogene · 2016Article
- Acetylation of C/EBPα inhibits its granulopoietic function.Nature communications · 2016Article
- Proteomic discovery of MNT as a novel interacting partner of E3 ubiquitin ligase E6AP and a key mediator of myeloid differentiation.Oncotarget · 2016Article
- E3 Ubiquitin Ligase Fbw7 Negatively Regulates Osteoblast Differentiation by Targeting Runx2 for Degradation.The Journal of biological chemistry · 2015Article
- Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma.The Journal of biological chemistry · 2015Article
- Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.Nature chemical biology · 2015Article
- Signal, transduction, and the hematopoietic stem cell.Rambam Maimonides medical journal · 2014Article
- Positive feedback between PU.1 and the cell cycle controls myeloid differentiation.Science (New York, N.Y.) · 2013Article
- Interaction and cooperation of the CCAAT-box enhancer-binding protein β (C/EBPβ) with the homeodomain-interacting protein kinase 2 (Hipk2).The Journal of biological chemistry · 2013Article
- E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.Cell death & disease · 2013Article
- Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes.Molecular and cellular biochemistry · 2013Article
- E3 ubiquitin ligase E6AP negatively regulates adipogenesis by downregulating proadipogenic factor C/EBPalpha.PloS one · 2013Article
- Article
- Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.The Journal of biological chemistry · 2011Article
- Upregulation of p21-activated Kinase 6 in rat brain cortex after traumatic brain injury.Journal of molecular histology · 2011Article
- Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia.International journal of hematology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional inactivation of transcription factors in hematopoietic stem cell development is involved in the pathogenesis of acute myeloid leukemia (AML). Stem cell regulator C/enhancer binding protein (EBP)alpha is among such transcription factors known to be inactive in AML. This is either due to mutations or inhibition by protein-protein interactions. Here, we applied a mass spectrometry-based proteomic approach to systematically identify putative co-activator proteins interacting with the DNA-binding domain (DBD) of C/EBP transcription factors. In our proteomic screen, we identified c-Jun N-terminal kinase (JNK) 1 among others such as PAK6, MADP-1, calmodulin-like skin proteins and ZNF45 as proteins interacting with DBD of C/EBPs from nuclear extract of myelomonocytic U937 cells. We show that kinase JNK1 physically interacts with DBD of C/EBPalpha in vitro and in vivo. Furthermore, we show that active JNK1 inhibits ubiquitination of C/EBPalpha possibly by phosphorylating in its DBD. Consequently, JNK1 prolongs C/EBPalpha protein half-life leading to its enhanced transactivation and DNA-binding capacity. In certain AML patients, however, the JNK1 mRNA expression and its kinase activity is decreased which suggests a possible reason for C/EBPalpha inactivation in AML. Thus, we report the first proteomic screen of C/EBP-interacting proteins, which identifies JNK1 as positive regulator of C/EBPalpha.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.